5′-Capping enzymes are targeted to pre-mRNA by binding to the phosphorylated carboxy-terminal domain of RNA polymerase II

Susan McCracken(Ontario Institute for Cancer Research), Nova Fong(Ontario Institute for Cancer Research), Emanuel Rosonina(Ontario Institute for Cancer Research), Krassimir Yankulov(Ontario Institute for Cancer Research), Greg M. Brothers(Ontario Institute for Cancer Research), David P. Siderovski(Ontario Institute for Cancer Research), Andrew Hessel(Ontario Institute for Cancer Research), Stephen Paul Foster(Ontario Institute for Cancer Research), Amgen EST Program(Ontario Institute for Cancer Research), Stewart Shuman(Ontario Institute for Cancer Research), David L. Bentley(Ontario Institute for Cancer Research)
Genes & Development
December 15, 1997
Cited by 534Open Access
Full Text

Abstract

We have investigated the role of the RNA Polymerase II (Pol II) carboxy-terminal domain (CTD) in mRNA 5' capping. Transcripts made in vivo by Pol II with a truncated CTD had a lower proportion of capped 5' ends than those made by Pol II with a full-length CTD. In addition, the enzymes responsible for cap synthesis, RNA guanylyltransferase, and RNA (guanine-7)-methyltransferase bound directly to the phosphorylated, but not to the nonphosphorylated, form of the CTD in vitro. These results suggest that: (1) Pol II-specific capping of nascent transcripts in vivo is enhanced by recruitment of the capping enzymes to the CTD and (2) capping is co-ordinated with CTD phosphorylation.


Related Papers

No related papers found

Powered by citation graph analysis